COLL Q3 2020 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$79M+8.5% YoY

Gross Profit

$48M60.9% margin

Operating Income

$20M24.8% margin

Net Income

$11M14.3% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$32M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$644M

Total Liabilities

$471M

Stockholders' Equity

$173M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$73M	+8.5%
Gross Profit	$48M	$26M	+84.0%
Operating Income	$20M	-$6M	+407.9%
Net Income	$11M	-$6M	+284.7%

Revenue Segments

Nucynta

$47M37%

Xtampza

$32M25%

Nucynta Ir

$30M24%

Nucynta Er

$17M14%